Trial Profile
Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Rezatomidine (Primary)
- Indications Fibromyalgia; Pain
- Focus Therapeutic Use
- Sponsors Allergan
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 May 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified February 2009).